These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2951064)

  • 21. Long term improvement in insulin response with gliclazide treatment.
    Bodansky HJ; Medback S; Cudworth AG; Rees LH; de Silva RS
    Diabete Metab; 1982 Dec; 8(4):319-22. PubMed ID: 6761187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study.
    Vestergaard H; Weinreb JE; Rosen AS; Bjørbaek C; Hansen L; Pedersen O; Kahn BB
    J Clin Endocrinol Metab; 1995 Jan; 80(1):270-5. PubMed ID: 7829624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
    Noury J; Nandeuil A
    Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of sulphonylureas in the elderly.
    Graal MB; Wolffenbuttel BH
    Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.
    Hosker JP; Burnett MA; Davies EG; Harris EA; Turner RC
    Diabetologia; 1985 Nov; 28(11):809-14. PubMed ID: 3936738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of type 2 diabetes mellitus with special reference to metformin therapy.
    Campbell IW
    Diabete Metab; 1991 May; 17(1 Pt 2):191-6. PubMed ID: 1936475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial.
    Shaw KM; Wheeley MS; Campbell DB; Ward JD
    Diabet Med; 1985 Nov; 2(6):484-90. PubMed ID: 2951123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Insulinotropic effect of diamicron after oral fructose tolerance test in patients with non-insulin-dependent diabetes mellitus].
    Balabolkin MI; Levitskaia ZI; Morozova TP; Zhizhina SA; Gavriliuk LI
    Probl Endokrinol (Mosk); 1983; 29(5):8-12. PubMed ID: 6359134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non-insulin-dependent diabetes and gliclazide].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1986; ():295-301. PubMed ID: 3302488
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No effect of gliclazide on gastric inhibitory polypeptide (GIP) in type II diabetes.
    Scott RS; Donnelly T
    Diabetes Res Clin Pract; 1987; 3(3):175-8. PubMed ID: 3595434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy.
    Samanta A; Burden AC; Jones GR; Clarkson L
    Diabetes Res; 1986 Jun; 3(5):269-71. PubMed ID: 3527524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1988; ():337-47. PubMed ID: 3050231
    [No Abstract]   [Full Text] [Related]  

  • 38. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Maifreni L; Duner E; Lisato G; Iavicoli M; Tiengo A
    Diabetologia; 1990 Nov; 33(11):688-95. PubMed ID: 2127573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors].
    Balabolkin MI; Nedosugova LV
    Ter Arkh; 1988; 60(12):91-6. PubMed ID: 3150136
    [No Abstract]   [Full Text] [Related]  

  • 40. Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics.
    Couturier E
    Diabetes Res Clin Pract; 1985-1986 Mar; 1(6):343-7. PubMed ID: 3915271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.